AmorChem

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

Triad Life Sciences, Inc. is a biotechnology company based in Memphis, Tennessee, that specializes in developing bioactive tissue-based materials and therapies aimed at treating acute and chronic wounds, soft tissue injuries, and other regenerative applications. Founded in 2017, the company focuses on bioactive extracellular matrix technologies to create innovative solutions for wound healing. Triad Life Sciences manufactures and distributes novel regenerative materials designed to effectively address complex surgical wounds, chronic stalled wounds, and burns. With a leadership team that collectively offers over 100 years of experience in regenerative medicine, Triad is committed to meeting unmet clinical needs with cost-effective and efficacious therapies.

Giiant Pharma is a preclinical-stage biotechnology company developing gut-restricted, tissue-targeted small molecule therapeutics for gastroenterology and inflammatory bowel diseases. Leveraging a proprietary Precision Delivery platform, it uses the gut microbiota to bioactivate and release active drug forms specifically in the lower GI tract, minimizing systemic exposure and potentially improving tolerability and efficacy. The company’s lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug designed to reduce inflammation in the colon. By focusing on localized delivery and reduced systemic exposure, Giiant aims to provide safer, more effective treatments for IBD and related GI conditions.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

Liminal BioSciences Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative treatments for patients with unmet medical needs, particularly focusing on rare and orphan diseases. The company operates through two main segments: Small Molecule Therapeutics and Plasma Derived Therapeutics. Its lead product candidate, fezagepras, targets idiopathic pulmonary fibrosis, respiratory diseases, and Alström Syndrome. In the Plasma Derived Therapeutics segment, Liminal BioSciences offers a Plasma Protein Purification System for extracting and purifying therapeutic proteins from human plasma and is developing Ryplazim for congenital plasminogen deficiency. Founded in 1992 and headquartered in Laval, Quebec, the company has a presence in Canada, the United Kingdom, and the United States. It was previously known as Prometic Life Sciences Inc. before rebranding in October 2019.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

SemaThera Inc. is a Montreal-based biotechnology company developing anti-semaphorin 3A therapies to treat ocular diseases, including diabetic macular edema and other retinopathies. It focuses on SEMA 3A protein inhibitors (TRAP inhibitors) designed to counteract pathological signaling in the retina. The company traces its origins to a spin-off from AmorChem Venture Fund 1 and leverages research from Dr. Mike Sapieha’s laboratory at Hôpital Maisonneuve-Rosemont. Founded in 2016, SemaThera aims to translate this science into new treatment options for retinal diseases.

Osprey Pharmaceuticals USA, Inc., established in 2008 and headquartered in San Francisco, specializes in developing protein therapeutics to treat inflammatory and immune diseases. Its primary focus is on advancing a pipeline of proprietary fusion proteins called Leukocyte Population Modulators (LPMs), designed to selectively target and neutralize chemokine-activated leukocytes involved in various inflammatory conditions. The company's lead candidate, CCL2-LPM, targeting the CCR2 chemokine receptor, is currently in Phase Ib clinical trials for treating IgA nephropathy, an inflammatory kidney disease.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Osprey Pharmaceuticals USA, Inc., established in 2008 and headquartered in San Francisco, specializes in developing protein therapeutics to treat inflammatory and immune diseases. Its primary focus is on advancing a pipeline of proprietary fusion proteins called Leukocyte Population Modulators (LPMs), designed to selectively target and neutralize chemokine-activated leukocytes involved in various inflammatory conditions. The company's lead candidate, CCL2-LPM, targeting the CCR2 chemokine receptor, is currently in Phase Ib clinical trials for treating IgA nephropathy, an inflammatory kidney disease.

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing prescription products aimed at addressing vitamin D insufficiency and secondary hyperparathyroidism (SHPT) linked to chronic kidney disease (CKD). The company has a portfolio of innovative therapies specifically designed to safely and effectively treat patients with vitamin D deficiency and SHPT across various stages of CKD. Additionally, Cytochroma is working on novel treatments targeting elevated blood phosphorus levels, or hyperphosphatemia, to enhance the management of SHPT in CKD patients.

Xanthus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, acquisition, and commercialization of small-molecule therapeutics. The company primarily focuses on creating innovative treatments for cancer and autoimmune disorders, aiming to address unmet medical needs in these areas. Through its research and development efforts, Xanthus Pharmaceuticals strives to advance therapeutic options that can improve patient outcomes and enhance the quality of care in oncology and immunology.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

NewBiotics is a U.S.-based biotechnology company founded in 1997, specializing in the discovery and development of therapeutics for cancer and infectious diseases. The company focuses on leveraging the mechanisms of drug resistance to create innovative drug molecules. Notably, NewBiotics has identified the presence of double-minute chromosomes, which are unique to cancer cells, and has developed technology for the purification of double-minute DNA from tumor cells. This approach aims to transform the challenges posed by drug resistance into therapeutic advantages, enabling the development of more effective treatments. The company was acquired by Celmed Biosciences in 2004, further integrating its expertise into a broader therapeutic framework.

Xanthus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, acquisition, and commercialization of small-molecule therapeutics. The company primarily focuses on creating innovative treatments for cancer and autoimmune disorders, aiming to address unmet medical needs in these areas. Through its research and development efforts, Xanthus Pharmaceuticals strives to advance therapeutic options that can improve patient outcomes and enhance the quality of care in oncology and immunology.

LymphoSign is a pharmaceutical company that is focused on the development of drugs for blood cancers. LymphoSign was acquired by Aegera Therapeutics in August 2007. LymphoSign was founded in 2000 and is based in Markham, Canada.

IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

Copernicus Therapeutics is a clinical-stage biopharmaceutical company developing non-viral delivery systems for nucleic acid drugs. Its proprietary platform enables robust, immune-response-free gene transfer in various tissues, with applications in treating cystic fibrosis and other serious diseases like macular degeneration, neurological disorders, and pulmonary conditions.

Scion Pharmaceuticals is a biotechnology company that specializes in the research and development of small-molecule drugs. The company's primary focus is on identifying and optimizing treatments for central nervous system (CNS) disorders and cardiovascular diseases. Scion Pharmaceuticals is known for its innovative approach to drug development, particularly in the area of ion channel modulators, which play a crucial role in various physiological processes. Through its targeted research services, the company aims to advance therapeutic options and improve patient outcomes in these critical areas of healthcare.

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

Aegera Therapeutics is a clinical stage biotechnology company that specializes in developing targeted therapeutics to meet significant unmet medical needs. The company has multiple clinical programs, focusing primarily on oncology and neuropathic pain. Its oncology initiatives include treatments for various cancers, such as chronic lymphocytic leukemia, acute myeloid leukemia, non-small cell lung cancer, pancreatic cancer, and hepatocellular carcinoma. Additionally, Aegera is exploring therapies for solid tumors and peripheral neuropathy in diabetic patients. The company also works on small molecule inhibitors aimed at treating multiple cancers, as well as inflammatory and autoimmune diseases. Aegera is committed to leveraging its core technologies and expertise to identify and advance novel development candidates from preclinical stages into clinical trials.

Founded in 2014, PhageTech develops innovative bacteriophage sensors for advanced diagnostics. Its technology enables early detection of various conditions like cancer, sepsis, and infectious diseases by analyzing urine, blood, and other bodily fluids. Based in Irvine, California.

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing prescription products aimed at addressing vitamin D insufficiency and secondary hyperparathyroidism (SHPT) linked to chronic kidney disease (CKD). The company has a portfolio of innovative therapies specifically designed to safely and effectively treat patients with vitamin D deficiency and SHPT across various stages of CKD. Additionally, Cytochroma is working on novel treatments targeting elevated blood phosphorus levels, or hyperphosphatemia, to enhance the management of SHPT in CKD patients.

Avalon Pharmaceuticals, founded in 1999 and headquartered in Germantown, Maryland, was a biopharmaceutical company dedicated to discovering, developing, and commercializing cancer therapeutics using its proprietary AvalonRx technology. Its lead product candidate, AVN944, an IMPDH inhibitor, was in Phase IIa clinical development for treating hematologic and solid cancers at the time of its acquisition by Clinical Data Inc. in 2009. The company collaborated with several prominent pharmaceutical companies, including Merck & Co., MedImmune, ChemDiv, Medarex, and Novartis, to advance its drug discovery and development efforts.

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing prescription products aimed at addressing vitamin D insufficiency and secondary hyperparathyroidism (SHPT) linked to chronic kidney disease (CKD). The company has a portfolio of innovative therapies specifically designed to safely and effectively treat patients with vitamin D deficiency and SHPT across various stages of CKD. Additionally, Cytochroma is working on novel treatments targeting elevated blood phosphorus levels, or hyperphosphatemia, to enhance the management of SHPT in CKD patients.

GeneFormatics is a biotechnology company that focuses on structural proteomics. It develops innovative function prediction methods aimed at the rapid identification of biologically relevant targets from extensive sequence data generated by global genomics projects. By harnessing advanced computational techniques, GeneFormatics contributes to the understanding of protein structures and functions, facilitating breakthroughs in biological research and potential therapeutic applications.

Interomex Biopharmaceuticals Inc. is dedicated to the identification of novel biological targets in key cellular processes with the aim of discovering lead compounds for the treatment of disease. The company’s proprietary Repressed Trans-activator (RTATM) technology can be used to detect protein-protein interactions between a host and an infectious agent, as well as within cells in normal and diseased states. A particular advantage of RTATM is its ability to detect the interactions of transcription transactivator proteins, which are key control points in viral infections and cell activation.

NewBiotics is a U.S.-based biotechnology company founded in 1997, specializing in the discovery and development of therapeutics for cancer and infectious diseases. The company focuses on leveraging the mechanisms of drug resistance to create innovative drug molecules. Notably, NewBiotics has identified the presence of double-minute chromosomes, which are unique to cancer cells, and has developed technology for the purification of double-minute DNA from tumor cells. This approach aims to transform the challenges posed by drug resistance into therapeutic advantages, enabling the development of more effective treatments. The company was acquired by Celmed Biosciences in 2004, further integrating its expertise into a broader therapeutic framework.

GeneFormatics is a biotechnology company that focuses on structural proteomics. It develops innovative function prediction methods aimed at the rapid identification of biologically relevant targets from extensive sequence data generated by global genomics projects. By harnessing advanced computational techniques, GeneFormatics contributes to the understanding of protein structures and functions, facilitating breakthroughs in biological research and potential therapeutic applications.

Elitra Pharmaceuticals in San Diego, CA is a private company categorized under Pharmaceutical Preparations. It was established in 1997 and incorporated in California.

Novalon Pharmaceuticals is a biopharmaceutical company focused on developing innovative drugs to address various medical needs. It leverages its technology access programs and therapeutic programs to create novel pharmaceutical solutions. The company's commitment to advancing healthcare is evident in its strategic approach to drug development, which aims to meet the demands of patients and healthcare providers alike. Through its research and development efforts, Novalon seeks to bring forth effective therapeutic options that improve patient outcomes.

Viron Therapeutics is a Biotechnology company

Ceptyr, Inc was founded to focus on developing drugs against protein tyrosine phosphatases (PTPs), a largely unexplored niche in pharmaceutical development.

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing prescription products aimed at addressing vitamin D insufficiency and secondary hyperparathyroidism (SHPT) linked to chronic kidney disease (CKD). The company has a portfolio of innovative therapies specifically designed to safely and effectively treat patients with vitamin D deficiency and SHPT across various stages of CKD. Additionally, Cytochroma is working on novel treatments targeting elevated blood phosphorus levels, or hyperphosphatemia, to enhance the management of SHPT in CKD patients.

BioVex Group is a biotechnology company specializing in the development and commercialization of biological treatments for cancer and infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine designed to target and destroy cancer cells while preserving surrounding healthy tissues. This innovative therapy utilizes a virus that replicates within solid tumors, leading to their destruction and stimulating a robust systemic immune response against the cancer. OncoVEXGM-CSF has undergone extensive clinical testing with over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and resulting in overall disease responses during Phase II trials. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes, further expanding its portfolio in biologic therapies.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on discovering and developing drugs to treat human diseases. Its pipeline includes candidates for irritable bowel syndrome, type 2 diabetes, rheumatoid arthritis, carcinoid syndrome, and glaucoma. The company has collaborations with major pharmaceutical companies and other organizations.

Copernicus Therapeutics is a clinical-stage biopharmaceutical company developing non-viral delivery systems for nucleic acid drugs. Its proprietary platform enables robust, immune-response-free gene transfer in various tissues, with applications in treating cystic fibrosis and other serious diseases like macular degeneration, neurological disorders, and pulmonary conditions.

The Medicines Company is a pharmaceutical firm dedicated to improving the treatment of critical care patients by offering innovative and cost-effective medicines to hospitals worldwide. The company's primary product, Angiomax, is an anticoagulant used in conjunction with aspirin for patients undergoing coronary angioplasty. Additionally, The Medicines Company markets Cleviprex, an injectable emulsion for managing blood pressure when oral medications are not suitable. In its development pipeline, the company has two late-stage products: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. Furthermore, The Medicines Company is exploring a serine protease inhibitor, CU2010, which is currently in early-stage development.

Message Pharmaceuticals is a company that provides Communications systems and more.

MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.

Gene Logic is a leading integrated genomics company providing comprehensive Genomic Reference Databases and GLP compliant Microarray Services. Over 2/3rd of the top 25 Pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred genomics partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets & biomarkers.